NirjiX
GCC by industry

GCC Strategy for Healthcare, Pharma and Life Sciences

Life-sciences centers carry a validation burden that generic GCC playbooks ignore. The question is not whether the work can move, but what qualification, training and audit evidence has to move with it.

Direct answer

What makes a life-sciences GCC different from a general services center?

Validated systems and qualified people. Work touching regulated records, clinical data, pharmacovigilance or manufacturing quality carries GxP obligations that travel with the process, not with the office. That means computer-system validation, documented training and qualification, and audit-ready change control from the first day — and it means the center is planned around inspection readiness rather than around seat cost.

Life-sciences organisations build capability centers for scientific and engineering depth as much as for cost: data management, biostatistics, regulatory operations, pharmacovigilance, quality systems and digital product engineering all have genuine talent depth in India.

The constraint is that most of this work is inspectable. A regulator or partner audit can arrive and ask for training records, validation evidence and deviation history for work performed offshore, and the answer has to be as complete as it would be at headquarters.

Where the depth genuinely is

Clinical data management, statistical programming, regulatory operations and safety case processing have mature talent pools with directly relevant experience, often built through years of service-provider work for the same sponsors. Quality systems, validation and digital engineering are also well supplied.

Wet-lab discovery science, regulatory strategy for a specific market, and final quality-person sign-off do not travel the same way. They depend on physical infrastructure or on named accountability in the home jurisdiction, and pretending otherwise creates an audit exposure.

  • Clinical data management and statistical programming
  • Pharmacovigilance case processing and signal support
  • Regulatory operations, publishing and submission management
  • Quality systems, CSV and digital product engineering

Inspection readiness is a design input

The practical test is simple: if an inspection arrives eighteen months after go-live, can the center produce role-qualification records, validated-system evidence, deviation and CAPA history, and a clear statement of who was accountable for each decision? If any of those answers depend on a person's memory, the design is not finished.

This shapes the transition method. Knowledge transfer for GxP work needs documented competency sign-off per process and per person, which takes longer than shadowing and reverse-shadowing on unregulated work. Compressing it to hit a cost date is the most common source of later findings.

Sequencing that holds up

Start with a wave that is genuinely inspectable but lower in risk — statistical programming, regulatory publishing, quality documentation — and use it to prove the qualification and evidence machinery works. Move safety case processing and clinical data management once that machinery has been tested by a real internal audit.

The temptation is to lead with the highest-volume, highest-saving process. In this sector that usually means safety operations, which is also the process where a finding is most damaging.

NirjiX view

Prove the evidence machinery on lower-risk work first

We would not open a life-sciences center with pharmacovigilance. We would open it with work that is regulated enough to exercise validation, training and change control, but where a first-year stumble is recoverable — then move the higher-consequence processes once an internal audit has confirmed the evidence trail is real.

The cost of that sequencing is a slower savings ramp by perhaps a wave. The benefit is that the center never has to defend an inspection finding it created for itself, which is the failure mode that ends sponsorship for these programmes.

What usually drives the decision

  • Clinical data management and biostatistics capacity
  • Pharmacovigilance and regulatory operations scale
  • Digital and data platforms for commercial and supply chain
  • Quality systems support across a widening product portfolio

Work that normally travels

  • Data & analytics
  • Quality, compliance & regulatory operations
  • Software engineering & product
  • Finance & accounting
  • R&D and design engineering

Work that normally stays

  • Qualified person and market authorisation accountability
  • Site-specific manufacturing quality decisions
  • Investigator and health-authority relationships

What good looks like

  • Validated systems requalified with the center in scope
  • Case processing and query turnaround at or better than baseline
  • First regulatory inspection passed with no critical finding

Sector constraints that decide the design

GxP and computer-system validation

Every validated system touched by the center needs requalification, role mapping and training records. Plan the validation calendar before the hiring plan.

Patient data handling

Pseudonymisation, cross-border transfer basis and retention rules decide which datasets the center can hold rather than only view.

Inspection readiness

The center becomes an inspectable site. SOPs, deviation handling and CAPA evidence must be live from day one, not at the first audit.

Operating model

Captive is the norm where GxP accountability is involved; managed or hybrid models work for non-validated digital, analytics and commercial support.

Designing it AI-native

Literature screening, case intake triage and document generation are the practical AI entry points — they change pharmacovigilance sizing materially and should be modelled before headcount is fixed.

Location notes

  • Hyderabad for a mature pharma and life-sciences ecosystem
  • Bengaluru and Pune for clinical data, engineering and analytics

Explore these cities

Hyderabad
Run the GCC feasibility assessment →Model the business case →Speak with a GCC expert →

GCC for Healthcare, pharma & life sciences — frequently asked questions

Can pharmacovigilance be run from an India GCC?
Yes, and many sponsors do. Case processing, triage, literature screening and signal support are all well established in India. The conditions are documented qualification for every person performing a regulated task, validated systems with an intact audit trail, and an accountability chain that ends with a named qualified person in the home jurisdiction. Move it as a later wave, once the evidence machinery has been tested.
Does GxP work require a captive entity?
Not strictly — regulated work is performed under service-provider models routinely. But sponsors carry the obligation regardless of who executes, so a captive simplifies the accountability chain and the audit narrative. Where speed matters, a build-operate-transfer route with sponsor-specified quality management is workable, provided the quality system is the sponsor's rather than the partner's.
How long does knowledge transfer take for regulated processes?
Longer than for unregulated work, because competency has to be documented per person and per process rather than demonstrated informally. Plan for a transition wave that ends with a signed qualification record and a period of dual running with formal quality review, and treat the exit criterion as evidence produced rather than time elapsed.
Which locations suit life-sciences capability centers?
Hyderabad and Bengaluru have the deepest clinical, regulatory and pharmacovigilance pools, with Pune and Chennai strong for engineering, quality and manufacturing-adjacent work. The right answer depends on your specific role mix — a center weighted to statistical programming shortlists differently from one weighted to device engineering.
What does AI change for life-sciences centers?
It compresses document-heavy effort in literature screening, submission drafting and safety narrative preparation, while raising the bar on oversight. The center's value moves toward validated deployment of those tools, review of their output, and the evidence that a human made the regulated decision. Size the case on that profile rather than on current manual volumes.
Why do healthcare, pharma & life sciences companies set up a GCC in India?
In healthcare, pharma & life sciences, the decision is usually driven by Clinical data management and biostatistics capacity; Pharmacovigilance and regulatory operations scale; Digital and data platforms for commercial and supply chain; Quality systems support across a widening product portfolio. Life-sciences centers carry a validation burden that generic GCC playbooks ignore. The question is not whether the work can move, but what qualification, training and audit evidence has to move with it.
Which healthcare, pharma & life sciences functions travel well to a GCC?
Work that normally moves first includes Data & analytics; Quality, compliance & regulatory operations; Software engineering & product; Finance & accounting; R&D and design engineering. Functions that normally stay at headquarters include Qualified person and market authorisation accountability; Site-specific manufacturing quality decisions; Investigator and health-authority relationships, because accountability for them cannot be relocated.
What usually constrains a healthcare, pharma & life sciences GCC design?
GxP and computer-system validation: Every validated system touched by the center needs requalification, role mapping and training records. Plan the validation calendar before the hiring plan. Patient data handling: Pseudonymisation, cross-border transfer basis and retention rules decide which datasets the center can hold rather than only view. Inspection readiness: The center becomes an inspectable site. SOPs, deviation handling and CAPA evidence must be live from day one, not at the first audit.
What operating model works for a healthcare, pharma & life sciences capability center?
Captive is the norm where GxP accountability is involved; managed or hybrid models work for non-validated digital, analytics and commercial support.
How should a healthcare, pharma & life sciences GCC be designed to be AI-native?
Literature screening, case intake triage and document generation are the practical AI entry points — they change pharmacovigilance sizing materially and should be modelled before headcount is fixed.
What does a successful healthcare, pharma & life sciences GCC look like?
Outcomes we look for are Validated systems requalified with the center in scope; Case processing and query turnaround at or better than baseline; First regulatory inspection passed with no critical finding. These are advisory judgements — the financial case comes from your own inputs in the GCC business case builder, not from generic benchmarks.
Which Indian cities suit a healthcare, pharma & life sciences GCC?
Hyderabad for a mature pharma and life-sciences ecosystem; Bengaluru and Pune for clinical data, engineering and analytics. Location fit is a shortlisting judgement; compare cities on the GCC locations pages and test the shortlist in the location finder.

The AI view of the same sector

Many healthcare, pharma & life sciences capability centers are built to run AI-enabled work. Our AI adoption view for the sector covers where the use cases pay off and what governance they require.

AI adoption in Healthcare, pharma & life sciences →

Other sector views

GCC for Financial servicesGCC for Manufacturing & industrialsGCC for Automotive & mobilityGCC for Technology & SaaS

This output is a preliminary, model-based view generated from the information you provided. It is an input to an advisory conversation, not a substitute for legal, tax or financial advice. Start with the GCC feasibility assessment.